Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, G.R. Doshi and K.M. Mehta Institute of Kidney Diseases and Research Center, Dr HL Trivedi Institute of Transplantation Sciences (IKDRC-ITS) , Ahmedabad, Gujarat , India .
Ren Fail. 2014 Apr;36(3):457-60. doi: 10.3109/0886022X.2013.868295. Epub 2013 Dec 17.
Transplantation tolerance is still a Utopian dream for many transplanters. Mesenchymal stem cells (MSC) have shown immuno-modulatory and tolerogenic effects in experimental models. We present a 29-year-old male with end stage renal disease (ESRD) who was transplanted with HLA 4/6 matched kidney from 51-year-old father in June 2010 preceded by co-infusion of donor-adipose tissue derived mesenchymal stem cells (AD-MSC) and bone marrow derived hematopoietic stem cells (BM-HSC) under non-myeloablative conditioning for deleting rejecting T and B-cells. He has maintained fairly stable graft function with serum creatinine (SCr) between 1.5 and 1.8 mg/dL at 3 years post-transplant with absence of donor specific antibodies (DSA), normal protocol graft biopsy, and peripheral T-regulatory cell levels (pTregs) (CD127(low/-)CD25(high)CD4+) of 4.57% on zero immunosuppression since 6 months.
移植耐受仍然是许多移植医生的一个乌托邦式的梦想。间充质干细胞（MSC）在实验模型中表现出免疫调节和耐受原性作用。我们介绍了一位 29 岁的男性，他患有终末期肾病（ESRD），于 2010 年 6 月接受了 HLA 4/6 匹配的肾脏移植，此前曾接受过供体脂肪组织来源的间充质干细胞（AD-MSC）和骨髓来源的造血干细胞（BM-HSC）共输注，以非清髓性条件预处理来清除排斥反应性 T 和 B 细胞。他在移植后 3 年的血清肌酐（SCr）保持在 1.5 至 1.8mg/dL 之间，功能相当稳定，没有供体特异性抗体（DSA），正常的方案移植活检，以及外周 T 调节细胞水平（pTregs）（CD127(low/-)CD25(high)CD4+）在零免疫抑制的情况下，自 6 个月以来为 4.57%。
